We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Alpha-1-Antitrypsin Gene Replacement Therapy Cures Emphysema in Mouse Model

By LabMedica International staff writers
Posted on 19 Jul 2016
Print article
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
A virus-like vector loaded with the gene for production of the enzyme alpha-1-antitrypsin (AAT) successfully established production of the protein in the lungs of mice serving as a model for human emphysema.

Alpha-1-antitrypsin protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. In its absence (such as in alpha 1-antitrypsin deficiency or AATD), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs, resulting in respiratory complications such as emphysema, or COPD (chronic obstructive pulmonary disease) in adults and cirrhosis in adults or children.

Gene therapy to reinstate AAT production in emphysema patients has been considered as an attractive alternative to the current therapy regime of weekly intravenous infusion of the normal AAT protein.

In one approach to developing gene therapy for treatment of emphysema, investigators at Boston Medical College (MA, USA) used a lung-targeted adeno-associated virus (AAV) vector to transport the AAT gene (SERPINA1) to the lungs of mice serving as a model for the human disease.

The investigators reported in the June 29, 2016, online edition of the journal Molecular Therapy - Methods & Clinical Development that the genes delivered in a single injection of lung-directed AAV2/8 were able to achieve therapeutic AAT protein levels within the lung epithelial lining fluid, and that gene expression persisted for at least 52 weeks. Enzyme levels reached after AAT gene delivery were sufficient to relieve the severity of experimental emphysema in the mice. They also found that the same injection of AAV2/8 efficiently transduced liver cells, a finding that may have significance for AAV-based human gene therapy studies.

"These results support direct transgene delivery to the lung as a potential alternative approach to achieve the goal of developing a gene therapy for AATD," said senior author Dr. Andrew Wilson, assistant professor of medicine at Boston Medical College.

Related Links:
Boston Medical College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.